Table 5: Base-case results for direct comparison of cost-effectiveness of pazopanib versus placebo.

PazopanibPlaceboPazopanib versus placebo

Effectiveness (discounted)
 LYs1.3751.2620.113
 PFLYs0.5030.2110.292
 PPLYs0.8721.051−0.179
 QALYs0.7190.5910.128
Costs (discounted), £
 Study medication10,733010,733
 Administration81081
 Adverse events25154197
 Other costs PFS557234323
 Other costs PPS10,46313,822−3,359
 Total22,08614,1107,976

Cost per QALY gained62,162

LYs: life-years; PFLYs: progression-free life-years; PFS: progression-free survival; PPLYs: postprogression life-years; PPS: postprogression survival; QALYs: quality-adjusted life-years.